サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：インフルエンザワクチンの世界市場（2022年～2028年）
市場調査レポート
商品コード
1215821

インフルエンザワクチンの世界市場（2022年～2028年）

Flu Influenza Vaccine Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
インフルエンザワクチンの世界市場（2022年～2028年）
出版日: 2023年01月25日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のインフルエンザワクチンの市場規模は、予測期間中に6.9%のCAGRで成長すると予測されています。当市場を牽引する主な要因には、市場の企業によるインフルエンザワクチン技術への投資などがあります。

当レポートでは、世界のインフルエンザワクチン市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、セグメント別、地域別の市場分析、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 世界のインフルエンザワクチン市場：ワクチンタイプ別
    • 四価
    • 三価
  • 世界のインフルエンザワクチン市場：技術別
    • 卵ベース
    • 細胞培養
  • 世界のインフルエンザワクチン市場：年齢層別
    • 小児
    • 成人
  • 世界のインフルエンザワクチン市場：投与経路別
    • 注射
    • 鼻スプレー

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋地域
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第6章 企業プロファイル

  • Abbott Laboratories
  • AstraZeneca plc
  • Biodiem
  • CPL Biologicals Pvt. Ltd
  • CSL Limited (Seqirus GmbH)
  • Emergent BioSolutions
  • F. Hoffmann-La Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • GlaxoSmithKline plc
  • MedImmune LLC (AstraZeneca plc)
  • Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sinovac Biotech Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL QUADRIVALENT FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL TRIVALENT FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
  • 5. GLOBAL FLU INFLUENZA VACCINE BY EGG-BASED MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL FLU INFLUENZA VACCINE BY CELL CULTURE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
  • 8. GLOBAL PEDIATRIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL ADULT FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 11. GLOBAL FLU INFLUENZA VACCINE IN INJECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL FLU INFLUENZA VACCINE IN NASAL SPRAY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
  • 16. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 19. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
  • 21. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
  • 23. EUROPEAN FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 24. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY VACCINE TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY TECHNOLOGY, 2021 VS 2028 (%)
  • 3. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 4. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
  • 5. GLOBAL FLU INFLUENZA VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL QUADRIVALENT FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 7. GLOBAL TRIVALENT FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 8. GLOBAL FLU INFLUENZA VACCINE BY EGG-BASED MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 9. GLOBAL FLU INFLUENZA VACCINE BY CELL CULTURE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 10. GLOBAL PEDIATRIC FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 11. GLOBAL ADULT FLU INFLUENZA VACCINE MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 12. GLOBAL FLU INFLUENZA VACCINE IN INJECTION MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 13. GLOBAL FLU INFLUENZA VACCINE IN NASAL SPRAY MARKET SHARE BY AGE GROUP, 2021 VS 2028 (%)
  • 14. US FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. CANADA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. UK FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. FRANCE FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. GERMANY FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. ITALY FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. SPAIN FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF EUROPE FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. INDIA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. CHINA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. JAPAN FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. SOUTH KOREA FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. REST OF ASIA-PACIFIC FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD FLU INFLUENZA VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026877

Title:Global Flu Influenza Vaccine Market Size, Share, and Trends Analysis Report, By Vaccine Type (Quadrivalent and Trivalent), By Technology (Egg-Based and Cell Culture), By Age Group (Pediatric and Adult), By Route of Administration (Injection and Nasal Spray), Forecast (2022 to 2028).

The global flu influenza vaccine market is anticipated to grow at a CAGR of 6.9% during the forecast period. The market players are investing in influenza vaccine technology which in turn, is offering an opportunity for market growth. For instance, in August 2021, the Seqirus business of CSL Ltd. Accelerated the development of its next generation of messenger RNA (mRNA) vaccine technology, self-amplifying messenger RNA (sa-mRNA), with the creation of a dedicated sa-mRNA program and senior leadership appointment. Moreover, the rising focus of major pharma companies on developing innovative vaccine solutions will further boost the influenza vaccine market.

The global flu influenza vaccine market is segmented based on type, technology, age group, and route of administration. Based on type, the market is segmented into quadrivalent and trivalent. Based on technology, the market is segmented into egg-based and cell culture. Furthermore, based on age group, it is bifurcated into pediatric and adult. Among these, the adult age group segment was the highest contributor to the influenza vaccine market in 2021 and is expected to remain dominant during the forecast period owing to the increasing geriatric population and the high risk of developing flu among them due to weaker immunity. Whereas based on the route of administration, the market is segmented into injection and nasal spray.

Geographically, the flu influenza vaccine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The market in the Asia-Pacific region is anticipated to experience the fastest growth during the forecast period owing to the increasing population in major economies such as China and India and the high prevalence of influenza virus among them which has surged the demand and development of influenza vaccines to combat flu diseases. Whereas North America is expected to dominate and hold the highest share owing to the increasing incidence of influenza outbreaks in countries such as the US.

The major market players in the global flu influenza vaccine market include AstraZeneca plc, GlaxoSmithKline plc, and Sanofi S.A., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global flu influenza vaccine is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Flu influenza vaccine Research and Analysis by Vaccine Type
  • Global Flu influenza vaccine Research and Analysis by Technology
  • Global Flu influenza vaccine Research and Analysis by Age Group
  • Global Flu influenza vaccine Research and Analysis by Route of Administration

The Report Covers:

  • Comprehensive research methodology of the global flu influenza vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global flu influenza vaccine market.
  • Insights about market determinants that are stimulating the global flu influenza vaccine market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Recovery Scenario of Global Flu Influenza Vaccine Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Flu Influenza Vaccine Market by Vaccine Type
    • 4.1.1. Quadrivalent
    • 4.1.2. Trivalent
  • 4.2. Global Flu Influenza Vaccine Market by Technology
    • 4.2.1. Egg-Based
    • 4.2.2. Cell Culture
  • 4.3. Global Flu Influenza Vaccine Market by Age Group
    • 4.3.1. Pediatric
    • 4.3.2. Adult
  • 4.4. Global Flu Influenza Vaccine Market by Route of Administration
    • 4.4.1. Injection
    • 4.4.2. Nasal Spray

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. Abbott Laboratories
  • 6.2. AstraZeneca plc
  • 6.3. Biodiem
  • 6.4. CPL Biologicals Pvt. Ltd
  • 6.5. CSL Limited (Seqirus GmbH)
  • 6.6. Emergent BioSolutions
  • 6.7. F. Hoffmann-La Roche Ltd.
  • 6.8. Gamma Vaccines Pty Ltd.
  • 6.9. GlaxoSmithKline plc
  • 6.10. MedImmune LLC (AstraZeneca plc)
  • 6.11. Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
  • 6.12. Mitsubishi Tanabe Pharma Corporation
  • 6.13. Novartis International AG
  • 6.14. Pfizer Inc.
  • 6.15. Sanofi S.A.
  • 6.16. Sinovac Biotech Ltd.